Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Korea Arlico Pharm (260660)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5,070 -10    -0.20%
02:10:37 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7260660006 
  • Volume: 5,219
  • Bid/Ask: 5,070 / 5,080
  • Day's Range: 5,050 - 5,100
Korea Arlico Pharm 5,070 -10 -0.20%

KQ:260660 Financials

 
A brief overview of the KQ:260660 financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Korea Arlico Pharm over time.

For the three months ended 31 March 2022, Korea Arlico Pharm Co Ltd revenues increased 37% to W42.93B. Net income increased 34% to W2.89B. Revenues reflect Special Medication segment increase of 34% to W41.78B, Other segment increase from W46M to W1.13B. Net income was partially offset by Marketing Commission increase of 36% to W20.19B (expense), Research & Development Expense increase of 97% to W2.28B (expense).

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

260660 Income Statement

Gross margin TTM 58.84%
Operating margin TTM 1.64%
Net Profit margin TTM 1.64%
Return on Investment TTM 2.12%
 Total Revenue  Net Income
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Total Revenue 50059.2 47551.31 44093.6 42383.82
Gross Profit 31048.74 29014.88 26517.08 28100.79
Operating Income 5310.27 3042.59 432.14 3473.72
Net Income 4680.91 2556.07 309.33 2396.29

260660 Balance Sheet

Quick Ratio MRQ 0.76
Current Ratio MRQ 1.19
LT Debt to Equity MRQ 7.57%
Total Debt to Equity MRQ 51.97%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Total Assets 164652.17 162506.01 153536.15 147712.54
Total Liabilities 70746.2 73318.46 64990.04 59883.51
Total Equity 93905.97 89187.56 88546.12 87829.03

260660 Cash Flow Statement

Cash Flow/Share TTM 466.35
Revenue/Share TTM 12,210.76
Operating Cash Flow  4.80%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 2934.47 3414.51 1464.13 -855.84
Cash From Investing Activities -2550.07 -5149.64 -5743.71 -3356.91
Cash From Financing Activities 25.42 3376.32 -245.55 5716.02
Net Change in Cash 417.61 1680.23 -4831.16 1636.02
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

260660 Comments

Write your thoughts about Korea Arlico Pharm
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email